Cronos Just Bought Europe's Top Cannabis Producer -- Is This the Catalyst Investors Have Waited 5 Years For?

"For years, North American cannabis investors have endured a brutal hangover. Cronos Group ( NASDAQ:CRON ), once a darling of the 2018-2019 marijuana mania, watched its share price collapse more than 95% from all-time highs as Canada's adult-use rollout disappointed, U.S. federal reform stalled, and oversupply crushed margins. Peers like Tilray Brands ( NASDAQ:TLRY ), Aurora Cannabis ( ), and Canopy Growth ( ) suffered similar fates. SAFE Banking failed to pass Congress, rescheduling talks dragged on, and the entire sector has traded like a forgotten penny stock despite billions in collective revenue. Hope has been in short supply . This morning, though, Cronos announced it was buying its way into Europe's most advanced adult-use market. After years of treading water, is Cronos finally a buy?"

"Cronos agreed to acquire 100% of CanAdelaar, the undisputed leader in the Netherlands' closely watched Wietexperiment - the only regulated adult-use supply program in Europe today - for $67 million in cash up front . Contingent earnouts of 0.5x normalized EBITDA for each of 2026 and 2027 will be paid in cash, keeping the total consideration reasonable. At roughly 1.4x CanAdelaar's trailing 12months revenue of $47.3 million and 2.4x its $28.2 million EBITDA, the price looks disciplined by cannabis M&A standards."

"What Cronos is really buying is the golden ticket: CanAdelaar has already hit paydirt. Out of the 10 licensed producers in the Dutch pilot, CanAdelaar is the only one operating a 540,000-square-foot greenhouse - the rest grow indoors at much higher cost. That scale has translated into dominant market share: CanAdelaar supplies flower, pre-rolls, hash, and edibles to nearly every one of the 72 participating coffee shops and currently commands the No. 1 position in Europe's largest regulated recreational market, estimated at well over $500 million annually once fully scaled."

Cronos Group is acquiring 100% of CanAdelaar for $67 million cash plus contingent earnouts tied to 2026 and 2027 normalized EBITDA. The transaction values CanAdelaar at roughly 1.4x trailing 12-month revenue and 2.4x EBITDA, representing a disciplined cannabis M&A multiple. CanAdelaar operates a 540,000-square-foot greenhouse and supplies flower, pre-rolls, hash, and edibles to nearly every one of the 72 participating Dutch coffee shops. The Netherlands pilot is the only regulated adult-use supply program in Europe and represents a market estimated well over $500 million annually when fully scaled. The acquisition provides Cronos immediate scale, lower-cost production, and leadership in Europe’s most advanced adult-use market.

Read at 24/7 Wall St.